Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3871801 in Moderately-to-Severely Active Rheumatoid Arthritis
NCT05848258Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of ocadusertib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started May 2023; status: completed.
02
Drugs
ocadusertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05848258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848258.